Abstract
Noninvasive circulating cell-free DNA (ccfDNA) has been proven to be useful for early cancer detection, prediction of disease recurrence and prognosis. In 2010, Casoni et al. suggested that serum ccfDNA may help discriminate idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases. We measured ccfDNA levels in a cohort of 45 therapy naive IPF patients (M=30; mean age: 65+/-12 years) and in 20 sex- and age-matched healthy controls (HCs). Plasma ccfDNA was extracted with the QIAm(R) MinElute ccfDNA it (Qiagen). Quantification was assessed with the automated Tape Station 2200 system (Aligent) that allows the differentiation of small length DNA fragments from genomic DNA contamination. We found that median values of ccfDNA were significantly higher in IPF than in HCs (1.41 vs 0.89 ng/mcl; p= 0.01). However, the distribution of ccfDNA levels was highly variable among IPF patients (range: 0.22-10.2 ng/mcl). Also, ccfDNA was not related to any demographic, clinical or lung function parameter. Further investigation in larger patient samples is needed to address the clinical usefulness of ccfDNA as diagnostic and prognostication biomarker of IPF.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4695.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019